NIR-triggered drug delivery system for chemo-photothermal therapy of posterior capsule opacification

Posterior capsule opacification (PCO) is the most common complication after cataract surgery and is likely to cause the second loss of vision. Pharmacological PCO prophylaxis has been proved to be effective, yet no clinical option is available due to the lack of a suitable mode of administration. In this work, we propose a unique concept of NIR dual-triggered drug release from black phosphorus (BP)-based implantable intraocular lens (IOL) for controlled drug release and chemo-photothermal combination therapy of PCO. Here, IOL is used as a reservoir of doxorubicin-loaded black phosphorus (BP-DOX), and BP is used as NIR activation agent for controlled drug release and photothermal therapy. This BP-DOX integrated IOL, namely BP-DOX@IOL, shows the characteristics of good transmittance, good mechanical property, NIR dual-triggered drug release behaviors, and excellent photothermal efficacy. In vivo studies reveal that there is no PCO occurrence in rabbits' model by using BP-DOX@IOL combined NIR irradiation, which exhibits distinct superiority on inhibiting PCO than the control group (100% PCO occurrence) 28 days post-surgery. This novel IOL drug delivery system would be a promising strategy for the future clinical application for PCO prophylaxis and treatment.

Automated summary

Posterior capsule opacification (PCO) is a common complication after cataract surgery, and pharmacological prophylaxis has been proven effective but lacks suitable clinical options. A novel concept of NIR dual-triggered drug release from black phosphorus-based implantable intraocular lens (IOL) for controlled drug release and chemo-photothermal combination therapy of PCO was proposed. The integrated IOL with black phosphorus-loaded doxorubicin showed good transmittance, mechanical properties, NIR dual-triggered drug release behaviors, and excellent photothermal efficacy, demonstrating promising results in inhibiting PCO in in vivo studies.